KURA Q3 2025 Earnings — Kura Oncology, Inc. Revenue & Financial Results | Market Cap Arena

KURAKura Oncology, Inc.

$815M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$21M

Gross Profit

$18M84.5% margin

Operating Income

-$80M-385.5% margin

Net Income

-$74M-357.2% margin

EPS (Diluted)

$-0.85

QoQ Revenue Growth

+35.7%

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$83M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$649M

Total Liabilities

$407M

Stockholders' Equity

$243M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$21M	$0	—
Gross Profit	$18M	$0	—
Operating Income	-$80M	-$60M	-33.6%
Net Income	-$74M	-$54M	-36.2%